Related Experiment Video
Updated: Mar 18, 2026

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
Published on: December 22, 2023
Rescuing cardiac automaticity in L-type Cav1.3 channelopathies and beyond
Pietro Mesirca1,2,3, Isabelle Bidaud4,5,6, Matteo E Mangoni7,8,9
1Département de Physiologie, Institut de Genomique Fonctionnelle, LabEx ICST, UMR-5203, Centre national de la recherche scientifique, F-34094, Montpellier, France. pietro.mesirca@igf.cnrs.fr.
Sick sinus syndrome (SSS) causes slow heart rate and is treated with pacemakers. Targeting compensatory ion channels, like IKACh, may offer new therapies for SSS and bradycardia.
Area of Science:
- Cardiology
- Molecular Biology
- Genetics
Background:
- Sick sinus syndrome (SSS) is a leading cause of bradycardia, necessitating pacemaker implantation.
- The incidence of SSS is projected to double in 50 years, highlighting the need for novel therapeutic strategies.
- Mutations in ion channels, particularly L-type Cav 1.3 channels, are implicated in inherited SSS.
Purpose of the Study:
- To investigate novel therapeutic targets for SSS beyond conventional pacemaker therapy.
- To explore the role of compensatory ion channel modulation in restoring sino-atrial node function.
Main Methods:
- Utilized a mouse model (Cav 1.3-/-) that recapitulates key features of SSS.
- Investigated the effects of targeting G protein-gated K+ (IKACh) channels in the Cav 1.3-/- mouse model.
Main Results:
- Cav 1.3 channel deficiency in mice mimics SSS, providing a valuable preclinical model.
- Targeting IKACh channels successfully rescued SSS phenotypes in Cav 1.3-/- mice.
Conclusions:
- Modulating compensatory ion channels presents a promising therapeutic avenue for SSS.
- This approach offers a new perspective on pacemaker mechanisms and potential treatments for bradycardia.
More Related Videos
11:32Determination of the Relative Cell Surface and Total Expression of Recombinant Ion Channels Using Flow Cytometry
Published on: September 28, 2016
08:52Generation of Murine Cardiac Pacemaker Cell Aggregates Based on ES-Cell-Programming in Combination with Myh6-Promoter-Selection
Published on: February 17, 2015
Related Concept Videos
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Cardiac Action Potential
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
Mechanism of Cardiac Arrhythmias
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Antihypertensive Drugs: Action of Calcium Channel Blockers